Search Results - "Mires, Derek E."

Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial by Ganguly, Siddhartha, Cortes, Jorge E., Krämer, Alwin, Levis, Mark J., Martinelli, Giovanni, Perl, Alexander E., Russell, Nigel H., Arunachalam, Meena, Santos, Cedric Dos, Gammon, Guy, Lesegretain, Arnaud, Mires, Derek E., Pham, Hoang, Wang, Yibin, Khaled, Samer K.

“…•Quizartinib enabled more patients to undergo hematopoietic stem cell transplantation (HSCT) versus chemotherapy.•Continuation of quizartinib after HSCT was…”
Get full text

Development of a quantitative systems pharmacology (QSP) model to support dose optimization of DS-1103a (anti SIRPa antibody) in combination with trastuzumab deruxtecan in patients with cancer by Cheng, Yougan, Vuppala, Pradeep, Sarma, Uddipan, Chelliah, Viji, Graaf, Piet van der, Karibe, Tsuyoshi, Hayashi, Shinko, Tsubaki, Takuya, Kawasaki, Norihito, Ishimoto, Yoko, Herrmann, Monika, Sue, Mayumi, Mires, Derek E., Toso, John F., Lau, Yvonne Y., Leil, Tarek

“…e14509 Background: DS-1103a, an anti-human signal regulatory protein α (SIRPα) monoclonal antibody (mAb), is designed to block the SIRPα-CD47 axis “Don’t Eat…”
Get full text

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML) by Zwaan, C. Michel, Kolb, Edward Anders, Mires, Derek E., Vigliotti, Michele, Xie, Jingdong, Downs, Pamela, DeCillis, Arthur P, Rabik, Cara A, Cooper, Todd M

“…▪ Background Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations occur in 10%-15% of pediatric/adolescent patients with AML and are…”
Get full text

Clinical Outcomes and Characteristics of Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial by Ganguly, Siddhartha, Cortes, Jorge E., Krämer, Alwin, Levis, Mark J., Martinelli, Giovanni, Perl, Alexander E., Russell, Nigel H., Arunachalam, Meena, Gammon, Guy, Lesegretain, Arnaud, Mires, Derek E., Namuyinga, Ruth, Zhang, Yufen, Khaled, Samer K.

“…▪ Introduction: In the phase 3 QuANTUM-R trial, once-daily, oral, highly potent and selective FLT3 inhibitor Q improved clinical benefits vs SC (median overall…”
Get full text

Characterization of Response and Transfusion Independence in Patients with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory Acute Myeloid Leukemia Treated with Quizartinib or Salvage Chemotherapy in the Quantum-R Trial by Levis, Mark J., Ganguly, Siddhartha, Khaled, Samer K., Krämer, Alwin, Martinelli, Giovanni, Perl, Alexander E., Russell, Nigel H., Choi, Youngsook, Lesegretain, Arnaud, Mendell, Jeanne, Mires, Derek E., Zhang, Yufen, Cortes, Jorge E.

“…▪ Introduction: Patients (pts) with relapsed/refractory (R/R) acute myeloid leukemia (AML) with FLT3-ITD mutations have a dismal prognosis and limited…”
Get full text

Effect of Co-Mutations and FLT3-ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) by Perl, Alexander E., Cortes, Jorge E., Ganguly, Siddhartha, Khaled, Samer K., Krämer, Alwin, Martinelli, Giovanni, Russell, Nigel H., Chang, Ken CN, Mires, Derek E., Kato, Kazunobu, Zhang, Yufen, Korkhov, Sergey, Wang, Zhenyu, Günnel, Tobias, Sumi, Hiroyuki, Isoyama, Takeshi, Lesegretain, Arnaud, Berisha, Flora, Dos Santos, Cedric E., Levis, Mark J.

“…▪ Background: Quizartinib, a once-daily, oral, highly potent and selective FLT3 inhibitor, demonstrated a significant improvement in survival vs SC in…”
Get full text

Clinical Outcomes and Characteristics of Patients (pts) with FLT3–Internal Tandem Duplication (FLT3-ITD)–Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial by Ganguly, Siddhartha, Cortes, Jorge E., Krämer, Alwin, Levis, Mark J., Martinelli, Giovanni, Perl, Alexander E., Russell, Nigel H., Arunachalam, Meena, Gammon, Guy, Lesegretain, Arnaud, Mires, Derek E., Khaled, Samer K.

“…In QuANTUM-R, the once-daily, oral, highly potent and selective FLT3 inhibitor Q improved clinical benefit vs SC (median overall survival [mOS], 6.2 vs 4.7 mo…”
Get full text